A pooled analysis across four clinical trials of delandistrogene moxeparvovec in Duchenne muscular dystrophy reported a “manageable” cardiac safety profile over up to five years of follow-up in predominantly young, ambulatory patients. The analysis focuses on long-term tolerability outcomes, supporting continued clinical development while monitoring cardiac risk in real-world treatment settings.